Trial · NCT04667104
Results by group211
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 211
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Percentage of Participants With a Reduction of at Least 2 log10 International Unit/Millilitres (IU/mL) in Hepatitis B Surface Antigen (HBsAg) Levels From Baseline to Week 24 | TP 2:JNJ-3989 200 mg+JNJ-6379 250 mg+PegIFN-alpha2a 180 mcg+NA | 64.6 | 90% Confidence Interval 51.73 | percentage of participants | |
| Percentage of Participants With Treatment Emergent Adverse Events (TEAEs) as a Measure of Safety and Tolerability | TP 1:JNJ-73763989 200 mg+JNJ-56136379 250 mg+NA | 52.1 | percentage of participants | ||
| Percentage of Participants With Treatment Emergent Adverse Events (TEAEs) as a Measure of Safety and Tolerability | TP 2:JNJ-3989 200 mg+JNJ-6379 250 mg+PegIFN-alpha2a 180 mcg+NA | 87.5 | percentage of participants | ||
| Percentage of Participants With Treatment Emergent Adverse Events (TEAEs) as a Measure of Safety and Tolerability | Follow-Up (FU) Period-nucleos(t)Ide Analog (NA) | 60.4 | percentage of participants | ||
| Percentage of Participants With Serious Adverse Events (SAEs) as a Measure of Safety and Tolerability | TP 1:JNJ-73763989 200 mg+JNJ-56136379 250 mg+NA | 0 | percentage of participants | ||
| Percentage of Participants With Serious Adverse Events (SAEs) as a Measure of Safety and Tolerability | TP 2:JNJ-3989 200 mg+JNJ-6379 250 mg+PegIFN-alpha2a 180 mcg+NA | 2.1 | percentage of participants | ||
| Percentage of Participants With Serious Adverse Events (SAEs) as a Measure of Safety and Tolerability | Follow-Up (FU) Period-nucleos(t)Ide Analog (NA) | 8.3 | percentage of participants | ||
| Number of Participants With Clinically Significant Abnormalities in Vital Signs as a Measure of Safety and Tolerability | TP 1:JNJ-73763989 200 mg+JNJ-56136379 250 mg+NA | 0 | Participants | ||
| Number of Participants With Clinically Significant Abnormalities in Vital Signs as a Measure of Safety and Tolerability | TP 2:JNJ-3989 200 mg+JNJ-6379 250 mg+PegIFN-alpha2a 180 mcg+NA | 0 | Participants | ||
| Number of Participants With Clinically Significant Abnormalities in Vital Signs as a Measure of Safety and Tolerability | Follow-Up (FU) Period-nucleos(t)Ide Analog (NA) | 0 | Participants | ||
| Number of Participants With Clinically Significant Abnormalities in Laboratory Findings as a Measure of Safety and Tolerability | TP 1:JNJ-73763989 200 mg+JNJ-56136379 250 mg+NA | Treatment-emergent (TE)-Grade 3 ALT elevations | 1 | Participants | |
| Number of Participants With Clinically Significant Abnormalities in Laboratory Findings as a Measure of Safety and Tolerability | TP 2:JNJ-3989 200 mg+JNJ-6379 250 mg+PegIFN-alpha2a 180 mcg+NA | Treatment-emergent (TE)-Grade 3 ALT elevations | 1 | Participants | |
| Number of Participants With Clinically Significant Abnormalities in Laboratory Findings as a Measure of Safety and Tolerability | Follow-Up (FU) Period-nucleos(t)Ide Analog (NA) | Treatment-emergent (TE)-Grade 3 ALT elevations | 1 | Participants | |
| Number of Participants With Clinically Significant Abnormalities in Laboratory Findings as a Measure of Safety and Tolerability | TP 1:JNJ-73763989 200 mg+JNJ-56136379 250 mg+NA | TE-Grade 3 total bilirubin elevations | 0 | Participants | |
| Number of Participants With Clinically Significant Abnormalities in Laboratory Findings as a Measure of Safety and Tolerability | TP 2:JNJ-3989 200 mg+JNJ-6379 250 mg+PegIFN-alpha2a 180 mcg+NA | TE-Grade 3 total bilirubin elevations | 0 | Participants | |
| Number of Participants With Clinically Significant Abnormalities in Laboratory Findings as a Measure of Safety and Tolerability | Follow-Up (FU) Period-nucleos(t)Ide Analog (NA) | TE-Grade 3 total bilirubin elevations | 1 | Participants | |
| Number of Participants With Clinically Significant Abnormalities in Laboratory Findings as a Measure of Safety and Tolerability | TP 1:JNJ-73763989 200 mg+JNJ-56136379 250 mg+NA | TE-Grade 3 direct bilirubin elevations | 0 | Participants | |
| Number of Participants With Clinically Significant Abnormalities in Laboratory Findings as a Measure of Safety and Tolerability | TP 2:JNJ-3989 200 mg+JNJ-6379 250 mg+PegIFN-alpha2a 180 mcg+NA | TE-Grade 3 direct bilirubin elevations | 0 | Participants | |
| Number of Participants With Clinically Significant Abnormalities in Laboratory Findings as a Measure of Safety and Tolerability | Follow-Up (FU) Period-nucleos(t)Ide Analog (NA) | TE-Grade 3 direct bilirubin elevations | 2 | Participants | |
| Number of Participants With Clinically Significant Abnormalities in Laboratory Findings as a Measure of Safety and Tolerability | TP 1:JNJ-73763989 200 mg+JNJ-56136379 250 mg+NA | Treatment-emergent-High serum indirect bilirubin | 0 | Participants |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT04667104/results